PHAROS

NCT03915951 📎

Regimen

Experimental
Treatment Period

Population

BRAF V600E-mutant metastatic NSCLC (phase II, single-arm)

Key finding

Updated efficacy and safety of enco+bini in BRAF V600E NSCLC.

Source: PMID 37270692

Timeline

  • Enrollment start: 2019-06-04 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.212)
  • CSCO NSCLC 2025 ⚠️ OCR source